V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330011871 | 330005612 | 1.85 | 71.6 | Palliative (P) | 2014-02-19 | 2014-10-18 | UKALL14- Ph 2 Induction + Imatinib | N | N | 330021734 | GEMCITABINE + PACLITAXEL |
| 330011872 | 330005619 | 0 | 63 | Curative (C) | 2016-12-28 | 2017-01-25 | STS Rhabdomyosarcoma RMS 2005 VA | null | null | 330021811 | DOXORUBICIN + OLARATUMAB |
| 330011873 | 330005621 | 1.79 | 80 | Palliative (P) | 2015-11-07 | 2015-11-08 | Ipilimumab | 02 | N | 330021850 | IPILIMUMAB |
| 330011874 | 330010925 | null | 88.3 | Palliative (P) | 2014-08-18 | 2015-03-08 | Dox + HD Mtx (post PAM) | null | null | 330021973 | FLAG |
| 330011875 | 330010926 | 1.64 | 68.2 | Palliative (P) | 2015-09-02 | 2015-09-08 | Carboplatin + Cetux + FU (>Cycle 2) | N | N | 330022010 | TRIPLE INTRATHECAL |
| 330011876 | 330012537 | 0 | null | Palliative (P) | 2018-07-30 | 2018-07-30 | Cyclophosphamide High Dose | N | N | 330022019 | CYCLOPHOSPHAMIDE + ETOPOSIDE |
| 330011877 | 330005634 | 1.9 | 22.2 | Curative (C) | 2016-01-11 | 2016-01-12 | Alemtuzumab + Cyclophos TBI Allo | 02 | N | 330022131 | CARBOPLATIN + DOCETAXEL + FLUOROURACIL |
| 330011878 | 330005637 | 1.82 | 48.6 | Curative (C) | 2018-03-24 | 2018-08-31 | Triple / Double Intrathecal Therapy | N | N | 330022152 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 330011879 | 330005641 | 1.73 | 56.4 | Palliative (P) | 2017-10-29 | 2017-10-29 | Hydroxycarbamide | null | N | 330022242 | CYCLOPHOSPHAMIDE |
| 330011880 | 330005648 | null | 77 | Curative (C) | 2019-08-11 | 2019-07-09 | CLADRIBINE | null | N | 330022274 | BLEOMYCIN + VINCRISTINE |
| 330011881 | 330005649 | null | 49 | Curative (C) | null | 2016-10-31 | BEP 5 Day | null | null | 330022302 | BEP |
| 330011882 | 330005651 | null | null | null | 2015-09-23 | 2015-10-04 | POMALIDOMIDE | N | N | 330022321 | CARBOPLATIN + CETUXIMAB + FU |
| 330011883 | 330011951 | null | 60.5 | Palliative (P) | 2013-11-28 | 2014-07-03 | Carboplatin + Thiotepa + Topotecan | N | null | 330022355 | VINORELBINE |
| 330011884 | 330005657 | 1.83 | 84.8 | Curative (C) | 2016-08-15 | 2016-10-02 | VINCRISTINE | N | N | 330022445 | GEMCITABINE |
| 330011885 | 330005658 | 1.62 | 61 | Disease modification (D) | 2017-07-13 | 2017-07-13 | Cisplatin + Gemcitabine (D 1 & 8) | null | null | 330022450 | TRIPLE INTRATHECAL |
| 330011886 | 330009091 | 1.72 | 73.5 | Curative (C) | 2016-01-21 | 2016-04-27 | Ifosfamide | N | N | 330022493 | IVA |
| 330011887 | 330005664 | null | 54.6 | Curative (C) | 2014-08-29 | 2014-08-29 | UKALL14- Ph 1 Induction | 2 | N | 330022530 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 330011888 | 330005670 | 1.58 | 13.3 | Palliative (P) | 2013-10-14 | 2013-12-29 | DOXORUBICIN + IFOSFAMIDE | Y | N | 330022662 | MA |
| 330011889 | 330010940 | null | 87.8 | Curative (C) | 2016-03-08 | 2018-04-29 | Melphalan IV High dose | N | N | 330022813 | UKALL2014 |
| 330011890 | 330009103 | null | 54.3 | Disease modification (D) | 2017-03-23 | 2017-03-29 | Doxorubicin + Gemcitabine | null | null | 330022926 | DOXORUBICIN + HD MTX |
| 330011891 | 330012874 | null | 80 | Palliative (P) | 2017-07-06 | 2017-07-13 | CNS LGG 2004 03 vinc weekly+ carbo | N | N | 330022938 | DOXORUBICIN + IFOSFAMIDE |
| 330011892 | 330005691 | 0 | 67 | Palliative (P) | 2017-04-10 | 2017-08-06 | VIDE | N | N | 330022958 | CISPLATIN + ETOPOSIDE + IFOSFAMIDE |
| 330011893 | 330005691 | 1.6 | null | Palliative (P) | 2017-12-20 | 2018-01-10 | Nilotinib | 02 | null | 330022958 | CAPECITABINE + OXALIPLATIN |
| 330011895 | 330005703 | 1.82 | 91 | Curative (C) | null | 2019-08-13 | DHAP | null | N | 330023021 | MABCUTE TRIAL |
| 330011896 | 330012543 | 1.68 | null | Palliative (P) | 2017-03-08 | 2017-05-10 | AML 18 TRIAL | 01 | Y | 330023053 | BEP |
| 330011897 | 330009112 | 1.65 | 77.2 | Palliative (P) | 2017-03-06 | 2017-04-06 | RUXOLITINIB | N | N | 330023058 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 330011898 | 330005709 | 1.6 | 75 | Palliative (P) | 2013-08-24 | 2013-08-24 | Ifosfamide | N | N | 330023091 | RUXOLITINIB |
| 330011899 | 330005711 | null | null | Disease modification (D) | 2016-07-17 | 2016-07-17 | Dacarbazine | N | null | 330023102 | IPO |
| 330011900 | 330011962 | 1.67 | 120.4 | Curative (C) | 2016-10-07 | 2016-10-07 | ALL UKALL2011 Consolidation A | 02 | N | 330023159 | BEP |
| 330011901 | 330005716 | 1.74 | 72.6 | Palliative (P) | 2014-06-27 | 2014-06-27 | Cisplatin + Gemcitabine (D 1 & 8) | 2 | N | 330023161 | CAPECITABINE + CISPLATIN |
| 330011902 | 330005718 | 1.72 | null | Curative (C) | 2015-11-13 | 2015-11-13 | Mitotane 5.5 - 10g | 02 | N | 330023226 | BEP |
| 330011903 | 330005720 | null | 0 | Palliative (P) | null | 2016-04-26 | ACE (germ cell) | null | null | 330023242 | BORTEZOMIB + RITUXIMAB |
| 330011904 | 330009126 | 1.72 | 60.5 | Palliative (P) | 2017-09-20 | 2017-10-17 | MAP + MIFAMURTIDE | Y | N | 330023274 | BEVACIZUMAB + IRINOTECAN |
| 330011905 | 330011964 | 1.7 | 96.5 | Curative (C) | 2018-09-02 | 2018-11-13 | CISPLATIN + DOXORUBICIN + METHOTREXATE | Y | null | 330023279 | CARBOPLATIN + VINCRISTINE |
| 330011907 | 330005742 | 1.76 | null | Palliative (P) | 2017-01-07 | 2018-06-07 | Eribulin | N | null | 330023355 | CYTARABINE |
| 330011908 | 330005751 | 1.6 | 120 | null | 2018-09-30 | 2019-02-14 | Ipilimumab | N | N | 330023377 | CARBOPLATIN + ETOPOSIDE + THIOTEPA |
| 330011909 | 330005754 | null | null | Curative (C) | null | 2013-07-28 | CNS LGG 2004 03 vinc weekly+ carbo | null | null | 330023405 | EMA/CO |
| 330011910 | 330005756 | null | null | Curative (C) | null | 2014-01-04 | Doxorubicin + Gemcitabine | null | null | 330023409 | CVD |
| 330011911 | 330010961 | 1.65 | 107.1 | Curative (C) | 2017-03-19 | 2017-03-19 | PAC-E | 02 | N | 330023440 | IVAC |
| 330011912 | 330005758 | 1.73 | 90.2 | Curative (C) | null | 2017-01-08 | VIDE | Y | N | 330023454 | CAPECITABINE + CARBOPLATIN |
| 330011913 | 330005765 | 1.68 | null | Neo-adjuvant (N) | 2013-02-09 | 2013-10-22 | BLEOMYCIN + CISPLATIN + VINCRISTINE | Y | N | 330023539 | AML19 TRIAL |
| 330011914 | 330005768 | null | 72.2 | Palliative (P) | null | 2018-01-02 | Hydroxycarbamide | Y | null | 330023548 | ICE |
| 330011915 | 330010966 | 0 | 119.5 | Palliative (P) | 2013-07-17 | 2013-08-20 | Triple / Double Intrathecal Therapy | Y | N | 330023606 | DOXORUBICIN + IFOSFAMIDE |
| 330011916 | 330005773 | 0 | null | Curative (C) | 2017-12-17 | 2017-12-21 | IVADo | 01 | N | 330023624 | CISPLATIN + PEMETREXED |
| 330011917 | 330005774 | null | 73.6 | Palliative (P) | 2013-10-17 | 2013-10-20 | ATG + Busulfan + Fludarabine | N | N | 330023647 | EMA |
| 330011918 | 330009151 | 1.81 | 73.9 | Curative (C) | 2015-12-08 | 2015-12-11 | Thalidomide 100mg | 02 | N | 330023705 | CAPECITABINE + CISPLATIN |
| 330011919 | 330005780 | 1.65 | 40.1 | Palliative (P) | null | 2017-07-27 | EMA | null | N | 330023722 | IBRUTINIB |
| 330011920 | 330005787 | 1.7 | 64.5 | Neo-adjuvant (N) | 2018-03-31 | 2018-03-31 | STS Rhabdomyosarcoma RMS 2005 VA | N | N | 330023758 | CETUXIMAB + CISPLATIN + FLUOROURACIL |
| 330011921 | 330005789 | 1.72 | 67 | Curative (C) | 2016-12-19 | 2017-04-03 | NCRN402 BEACON TRIAL | N | N | 330023791 | IPILIMUMAB |
| 330011922 | 330011977 | 0 | null | Disease modification (D) | null | 2015-09-07 | DHAP | N | N | 330023810 | IFOSFAMIDE |